Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 35 peer-reviewed journal articles Updated
Endocrinology

Does Beta-Thalassemia Major Affect Growth & Puberty?

At a Glance

Children with beta-thalassemia major may experience delayed growth and puberty because iron from frequent blood transfusions can damage the pituitary gland. With strict iron chelation therapy and hormone replacement, these delays can be effectively managed so children develop normally.

In this answer

2 sections

01

The Role of Iron Overload in Development

02

Managing and Correcting Growth Delays

Children and teenagers with beta-thalassemia major can absolutely grow to a normal height and go through puberty, but many will need medical assistance to do so. The frequent blood transfusions required to treat the condition cause iron to build up in the body [1][2]. If this excess iron is not fully removed by chelation therapy, it can accumulate in the pituitary gland (a pea-sized organ at the base of the brain that acts as the control center for hormones) [3][4]. When iron damages the pituitary gland, it stops producing the signals needed for growth and puberty, leading to delayed physical development [5][6]. Fortunately, with close monitoring and hormone replacement therapies, these delays can be successfully managed so your child develops normally.

The Role of Iron Overload in Development

The endocrine system is a network of glands that produce hormones, which are the chemical messengers responsible for growth, puberty, and reproduction. In beta-thalassemia major, chronic iron overload from blood transfusions causes oxidative stress—chemical damage to cells—which is especially harmful to endocrine organs [7][8].

  • Hypogonadism: The most common endocrine complication is hypogonadotropic hypogonadism, a condition where the pituitary gland fails to send signals (gonadotropins like LH and FSH) to the testicles or ovaries [3][9]. Without these signals, the body does not naturally produce testosterone or estrogen, resulting in delayed, arrested, or absent puberty [3][10]. This condition is also a primary cause of infertility in thalassemia patients; however, with careful medical management and specialized reproductive treatments later in life, many patients can go on to build families [3][11].
  • Growth Hormone Deficiency: Iron buildup can also prevent the pituitary gland from releasing enough growth hormone [12][13]. This deficiency, alongside lower levels of an associated growth factor called IGF-1, slows down the child’s overall growth rate and bone development [14][15].
  • Other Contributing Factors: While iron overload is the primary cause, deficiencies in zinc (a vital mineral for immune and metabolic function) and Vitamin D (essential for calcium absorption and bone health) are also very common in thalassemia and can further impair skeletal growth [16][17][18]. Rather than starting supplements on your own, ask your doctor to routinely monitor these levels during your child’s standard blood tests.

Managing and Correcting Growth Delays

Preventing and treating growth delays requires a proactive partnership with an endocrinologist (a doctor who specializes in hormones). Early intervention is key to ensuring your child’s bones and body mature safely.

1. Optimizing Iron Chelation

The most critical step in protecting the endocrine system is strict adherence to iron chelation therapy [19][20][21]. While managing daily chelation can be physically and emotionally exhausting for both you and your child, removing excess iron not only prevents further damage to the pituitary gland but, if caught early enough, can sometimes reverse early endocrine issues [22][5]. Doctors may use specialized imaging, such as a T2 MRI* (a specific type of magnetic resonance imaging that detects iron concentration in tissues), to spot iron buildup in the pituitary gland long before symptoms appear [23][24][25].

2. Hormone Replacement Therapy (HRT)

If the pituitary gland is damaged, the missing hormones can be replaced through careful medical management and ongoing monitoring. Hormone replacement is a standard and effective way to induce puberty and support healthy growth:

  • Growth Hormone: If tests reveal a true growth hormone deficiency, daily injections of synthetic growth hormone can help a child reach a normal adult height [13][15].
  • Pubertal Induction: If puberty does not begin naturally by the early teenage years (typically around ages 12 to 14), doctors will carefully initiate puberty using hormone therapies [26][27]. These regimens are carefully tailored to mimic the gradual progression of natural puberty. For boys, this involves gradually increasing doses of testosterone (often given via injections or gels) to restore natural physical changes and improve bone mass [28][29][30]. For girls, estrogen is introduced first, eventually followed by progesterone, to safely mimic a natural pubertal cycle and protect ovarian health [31][32].
  • Protecting Bone Health: Replacing these hormones is vital not just for appearance, but because both testosterone and estrogen are critical for building bone density and preventing fractures as your child grows [33][34][35].

Common questions in this guide

Why does beta-thalassemia major cause delayed puberty?
Frequent blood transfusions lead to iron buildup in the body. If not properly cleared by chelation therapy, this excess iron can damage the pituitary gland, stopping the signals needed for natural growth and puberty.
Can a child with beta-thalassemia reach a normal adult height?
Yes. With close monitoring, strict iron chelation therapy to remove excess iron, and potential growth hormone treatments, children with beta-thalassemia major can achieve a normal adult height.
What treatments are used to help induce puberty in thalassemia patients?
If puberty does not begin naturally by the early teenage years, doctors often use hormone replacement therapy. This typically involves gradually increasing doses of testosterone for boys, and estrogen followed by progesterone for girls.
How do doctors check for pituitary gland damage before symptoms appear?
Endocrinologists may use a specialized imaging scan called a T2* MRI. This scan detects iron concentration in tissues, allowing doctors to spot iron buildup in the pituitary gland long before any physical symptoms of delayed growth appear.
Can vitamin deficiencies affect growth in beta-thalassemia major?
While iron overload is the primary cause of delayed development, deficiencies in zinc and Vitamin D are also very common in thalassemia and can further impair a child's skeletal growth.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the current trend of my child's height and weight on their growth chart compared to peers?
  2. 2.Has a T2* MRI been performed recently to specifically assess the level of iron deposition in my child's pituitary gland?
  3. 3.What are my child's current IGF-1 levels, and do they warrant a formal growth hormone stimulation test?
  4. 4.If physical signs of puberty do not appear naturally, at what specific age do you recommend we begin discussing pubertal induction therapies?
  5. 5.Are we consistently testing for and optimizing all other growth factors, such as zinc and Vitamin D levels, during routine bloodwork?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

New Meds to Reduce Beta-Thalassemia Transfusions?Does Beta-Thalassemia Gene Therapy Cause Infertility?Why Does Beta-Thalassemia Cause Bone & Facial Changes?How Do Zynteglo & Casgevy Work for Beta-Thalassemia?How to Manage Teen Beta-Thalassemia Treatment BurnoutChances of Beta-Thalassemia Major for Carrier ParentsWhat Happens If You Miss Iron Chelation Doses?What Is a Cardiac T2* MRI for Thalassemia?How Much Do Zynteglo and Casgevy Gene Therapies Cost?What Is the Life Expectancy for Beta-Thalassemia Major?What is the Pesaro Score for Stem Cell Transplants?Why Do You Need Vision & Hearing Exams With Chelation?Why Do Beta-Thalassemia Symptoms Start at 3-6 Months?Why is Spleen Removal Needed for Beta-Thalassemia?

References

References (35)
  1. 1

    Musculoskeletal imaging manifestations of beta-thalassemia.

    Hajimoradi M, Haseli S, Abadi A, Chalian M

    Skeletal radiology 2021; (50(9)):1749-1762 doi:10.1007/s00256-021-03732-9.

    PMID: 33559685
  2. 2

    Anthropometric measurements in children having transfusion-dependent beta thalassemia.

    Moiz B, Habib A, Sawani S, et al.

    Hematology (Amsterdam, Netherlands) 2018; (23(4)):248-252 doi:10.1080/10245332.2017.1396044.

    PMID: 29086659
  3. 3

    Chronic iron overload disrupts the reproductive tract and leads to infertility: From a clinical case report to the experimental study of reproduction in female mice.

    da Costa CS, Marques VB, Mageski J, et al.

    Reproductive toxicology (Elmsford, N.Y.) 2025; (137()):109031 doi:10.1016/j.reprotox.2025.109031.

    PMID: 40816689
  4. 4

    Pituitary Volume and Iron Overload Evaluation by 3T MRI in Thalassemia.

    Nayak AM, Choudhari A, Patkar DP, Merchant RH

    Indian journal of pediatrics 2021; (88(7)):656-662 doi:10.1007/s12098-020-03629-w.

    PMID: 33675027
  5. 5

    A novel hepcidin mutation.

    Praeger-Jahnsen L, Magnussen K, Schiødt FV, et al.

    Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine 2023; (30(3)):335-340 doi:10.1016/j.tracli.2023.03.001.

    PMID: 36925058
  6. 6

    Pubertal Development and its Determinants in Adolescents With Transfusion-Dependent Thalassemia.

    Singh P, Samaddar S, Parakh N, et al.

    Indian pediatrics 2021; (58(7)):635-638.

    PMID: 33772533
  7. 7

    Complications in patients with transfusion dependent thalassemia: A descriptive cross-sectional study.

    Faranoush M, Faranoush P, Heydari I, et al.

    Health science reports 2023; (6(10)):e1624 doi:10.1002/hsr2.1624.

    PMID: 37841947
  8. 8

    A New Perspective for Potential Organ Damage Due to Iron-Mediated Oxidation in Thalassemia Major Patients.

    Eren F, Koca Yozgat A, Firat Oğuz E, et al.

    Journal of clinical medicine 2023; (12(6)) doi:10.3390/jcm12062422.

    PMID: 36983421
  9. 9

    A Rare Presentation of Transfusional Hemochromatosis: Hypogonadotropic Hypogonadism.

    Ucler R, Kara E, Atmaca M, et al.

    Case reports in endocrinology 2015; (2015()):493091 doi:10.1155/2015/493091.

    PMID: 26266058
  10. 10

    Pathogenic Mechanisms in Thalassemia II: Iron Overload.

    Ganz T, Nemeth E

    Hematology/oncology clinics of North America 2023; (37(2)):353-363 doi:10.1016/j.hoc.2022.12.006.

    PMID: 36907608
  11. 11

    Hypogonadotropic hypogonadism in men with hereditary hemochromatosis.

    El Osta R, Grandpre N, Monnin N, et al.

    Basic and clinical andrology 2017; (27()):13 doi:10.1186/s12610-017-0057-8.

    PMID: 28694969
  12. 12

    Framework for the comprehensive screening for endocrine disorders in patients with transfusion-dependent thalassemia in low-resource settings.

    Abbas S, Khan MO, Arif A, et al.

    Annals of hematology 2025; (104(9)):4391-4409 doi:10.1007/s00277-025-06577-7.

    PMID: 40987949
  13. 13

    New Entity-Thalassemic Endocrine Disease: Major Beta-Thalassemia and Endocrine Involvement.

    Carsote M, Vasiliu C, Trandafir AI, et al.

    Diagnostics (Basel, Switzerland) 2022; (12(8)) doi:10.3390/diagnostics12081921.

    PMID: 36010271
  14. 14

    Endocrinopathies in beta thalassemia: a narrative review.

    Venou TM, Barmpageorgopoulou F, Peppa M, Vlachaki E

    Hormones (Athens, Greece) 2024; (23(2)):205-216 doi:10.1007/s42000-023-00515-w.

    PMID: 38103163
  15. 15

    GH/IGF-1 axis in a large cohort of ß-thalassemia major adult patients: a cross-sectional study.

    Gagliardi I, Mungari R, Gamberini MR, et al.

    Journal of endocrinological investigation 2022; (45(7)):1439-1445 doi:10.1007/s40618-022-01780-z.

    PMID: 35305249
  16. 16

    Vitamin D Deficiency among Blood Transfusion Dependent Beta Thalassemia Children Admitted to Tertiary Level Pediatric Hospital in Nepal: A Descriptive Cross-sectional Study.

    Shrestha AK, Sherpa SC, Gyawali B, et al.

    JNMA; journal of the Nepal Medical Association 2024; (62(278)):621-626 doi:10.31729/jnma.8779.

    PMID: 40655881
  17. 17

    The effect of zinc deficiency and iron overload on endocrine and exocrine pancreatic function in children with transfusion-dependent thalassemia: a cross-sectional study.

    Mousa SO, Abd Alsamia EM, Moness HM, Mohamed OG

    BMC pediatrics 2021; (21(1)):468 doi:10.1186/s12887-021-02940-5.

    PMID: 34686155
  18. 18

    Vitamin D deficiency and its relationship with cardiac iron and function in patients with transfusion-dependent thalassemia at Chiang Mai University Hospital.

    Dejkhamron P, Wejaphikul K, Mahatumarat T, et al.

    Pediatric hematology and oncology 2018; (35(1)):52-59 doi:10.1080/08880018.2018.1424280.

    PMID: 29359982
  19. 19

    Ovarian function compromise in pediatric beta-thalassemia major: a consequence of iron overload-induced mitochondrial and fibrotic damage.

    Liu X, Chen P, Li Y, et al.

    Human reproduction (Oxford, England) 2026; (41(3)):410-426 doi:10.1093/humrep/deaf250.

    PMID: 41481664
  20. 20

    [Guidelines for iron chelation therapy in thalassemia in China (2025)].

    , , ,

    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2025; (27(4)):377-388 doi:10.7499/j.issn.1008-8830.2411001.

    PMID: 40241354
  21. 21

    Clinical utility of serum ferritin thresholds for guiding iron chelation therapy when magnetic resonance imaging is unavailable in patients with non-transfusion-dependent thalassaemias - response to Ang et al.

    Taher AT

    British journal of haematology 2017; (176(6)):989-990 doi:10.1111/bjh.14018.

    PMID: 26969908
  22. 22

    Iron chelation therapy for children with transfusion-dependent β-thalassemia: How young is too young?

    Forni GL, Kattamis A, Kuo KHM, et al.

    Pediatric blood & cancer 2024; (71(8)):e31035 doi:10.1002/pbc.31035.

    PMID: 38753107
  23. 23

    Iron Overload in Chronic Kidney Disease: Less Ferritin, More T2*MRI.

    Nashwan AJ, Yassin MA, Mohamed Ibrahim MI, et al.

    Frontiers in medicine 2022; (9()):865669 doi:10.3389/fmed.2022.865669.

    PMID: 35386917
  24. 24

    Quantitative T2* imaging of iron overload in a non-dedicated center - Normal variation, repeatability and reader variation.

    Lidén M, Adrian D, Widell J, et al.

    European journal of radiology open 2021; (8()):100357 doi:10.1016/j.ejro.2021.100357.

    PMID: 34095355
  25. 25

    Evaluation of cardiac and hepatic iron overload in thalassemia major patients with T2* magnetic resonance imaging.

    Wahidiyat PA, Liauw F, Sekarsari D, et al.

    Hematology (Amsterdam, Netherlands) 2017; (22(8)):501-507 doi:10.1080/10245332.2017.1292614.

    PMID: 28218005
  26. 26

    Testosterone Therapy in Adolescent Boys: The Need for a Structured Approach.

    Stancampiano MR, Lucas-Herald AK, Russo G, et al.

    Hormone research in paediatrics 2019; (92(4)):215-228 doi:10.1159/000504670.

    PMID: 31851967
  27. 27

    The experience of a tertiary unit on the clinical phenotype and management of hypogonadism in female adolescents and young adults with transfusion dependent thalassemia.

    De Sanctis V, Soliman AT, Daar S, et al.

    Acta bio-medica : Atenei Parmensis 2019; (90(1)):158-167 doi:10.23750/abm.v90i1.8143.

    PMID: 30889170
  28. 28

    Role of sex steroids hormones in the regulation of bone metabolism in men: Evidence from clinical studies.

    Szulc P

    Best practice & research. Clinical endocrinology & metabolism 2022; (36(2)):101624 doi:10.1016/j.beem.2022.101624.

    PMID: 35165044
  29. 29

    Testosterone replacement therapy.

    Barbonetti A, D'Andrea S, Francavilla S

    Andrology 2020; (8(6)):1551-1566 doi:10.1111/andr.12774.

    PMID: 32068334
  30. 30

    Blood donation and testosterone replacement therapy.

    Chin-Yee B, Lazo-Langner A, Butler-Foster T, et al.

    Transfusion 2017; (57(3)):578-581 doi:10.1111/trf.13970.

    PMID: 28150363
  31. 31

    Assessment of the ovarian reserve in patients with beta-thalassemia major: a prospective longitudinal study

    Özcan A, Gülseren V, Özcan E, et al.

    Journal of the Turkish German Gynecological Association 2023; (24(3)):159-164 doi:10.4274/jtgga.galenos.2023.2022-12-2.

    PMID: 37351586
  32. 32

    A 10-year longitudinal study of evaluation of ovarian reserve in women with transfusion-dependent beta thalassaemia major.

    Talaulikar VS, Bajoria R, Ehidiamhen AJ, et al.

    European journal of obstetrics, gynecology, and reproductive biology 2019; (238()):38-43 doi:10.1016/j.ejogrb.2019.04.046.

    PMID: 31082742
  33. 33

    Effect of Iron Overload on Bone Mineral Density in Patients with Transfusion-dependent Thalassemia.

    Gupta S, Bhargava S, Kumar R, Kakkar S

    The Journal of the Association of Physicians of India.. 2025; (73(6)):40-44 doi:10.59556/japi.73.1029.

    PMID: 40553589
  34. 34

    Metabolic Bone Disease in Children With Transfusion-Dependent Thalassemia.

    Handattu K, Aroor S, Kini P, et al.

    Indian pediatrics 2022; (59(12)):920-923.

    PMID: 36036187
  35. 35

    Bone health in ageing men.

    David K, Narinx N, Antonio L, et al.

    Reviews in endocrine & metabolic disorders 2022; (23(6)):1173-1208 doi:10.1007/s11154-022-09738-5.

    PMID: 35841491

This page provides educational information on how beta-thalassemia major affects pediatric growth and puberty. It is for informational purposes only and does not replace professional medical advice from your child's endocrinologist or hematologist.

Get notified when new evidence is published on Beta-thalassemia major.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.